Manager
RENTA 4 GESTORA, S.G.I.I.C., S.A.
See the CNMV manager universe →
Fund page
TRUE VALUE, FI
Category
—
Latest period
H1 2026
Positions
36
Portfolio as of 2026-06-30. Source: periodic filing with the CNMV. View original filing (PDF)
Full portfolio
Every position in the latest periodic filing, largest weight first. Aggregates ("other equities...") are baskets of small positions the filing itself does not break out line by line.
36
Company
Type
Country
Weight
Price
This period's moves
H1 2026 vs H2 2025 (estimated)
New: 6
Exits: 3
Increases: 13
Cuts: 6
− goeasy Ltd
Leaves the portfolio; it was 5.56% of weight.
− Jackson Financial Inc
Leaves the portfolio; it was 2.09% of weight.
− Repsol SA
Leaves the portfolio; it was 1.83% of weight.
▲ Keck Seng Investments
Goes from 4.63% to 6.58%.
Keck Seng Investments (Hong Kong) Limited, an investment holding company, engages in hotel and club operations, and property investment, development, and management activities in Macau, Vietnam, the People's Republic of China, Japan, Canada, the United States, and Hong Kong. It operates through three segments: Hotel; Property; and Investment and Corporate. The Hotel segment offers hotel room accommodation services; and food and beverages at hotel restaurant outlets, as well as operates slot machines. The Property segment leases investment properties, which primarily consist of retail, commercial, and office properties; and develops, markets, and sells trading properties. Keck Seng Investments (Hong Kong) Limited was incorporated in 1973 and is based in Central, Hong Kong.
View company page →▲ Fairfax India Holdings Corp
Goes from 1.11% to 1.50%.
Fairfax India Holdings Corporation, together with its subsidiaries, operates as an investment holding company in India. It invests in public and private equity securities and debt instruments, as well as Indian businesses or other businesses with customers, suppliers, or business. The company was incorporated in 2014 and is headquartered in Toronto, Canada.
View company page →▲ Amrize Ltd
Goes from 0.97% to 1.19%.
Amrize AG engages in the provision of various building solutions for infrastructure, commercial, and residential construction markets in North America and Canada. It operates through two segments, Building Materials and Building Envelope. The Building Materials segment offers cement and aggregates, as well as ready-mix concrete, asphalt, and other construction materials. The Building Envelope segment provides advanced roofing and wall systems, including single-ply membranes, insulation, shingles, sheathing, waterproofing, and protective coatings; and adhesives, tapes, and sealants. The company was formerly known as Holcim North America Finance Ltd and changed its name to Amrize AG in December 2013. Amrize AG was incorporated in 2023 and is based in Zug, Switzerland.
View company page →▼ Teva Pharmaceutical Industries
Goes from 2.63% to 1.83%.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
View company page →Disclaimer
This is not financial advice. The portfolio comes from the periodic report the fund files with the CNMV and lags the real close of the period: it is a snapshot of the end of each half-year, not a real-time portfolio.